Search
Search Results
-
Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer
HER2-positive (HER2+) breast cancer accounts for 20–25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to...
-
Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2− breast cancer subtypes
PurposeThis study compared the demographic and clinicopathologic characteristics and risk of mortality between the triple positive (TP) and...
-
Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study
BackgroundMultiple clinical trials demonstrate consistent but modest benefit of adjuvant extended endocrine therapy (EET) in HR + breast cancer...
-
Paradoxical cancer cell proliferation after FGFR inhibition through decreased p21 signaling in FGFR1-amplified breast cancer cells
Fibroblast growth factors (FGFs) control various cellular functions through fibroblast growth factor receptor (FGFR) activation, including...
-
Inhibition of lysine acetyltransferase KAT6 in ER+HER2− metastatic breast cancer: a phase 1 trial
Inhibition of histone lysine acetyltransferases (KATs) KAT6A and KAT6B has shown antitumor activity in estrogen receptor-positive (ER + ) breast cancer...
-
Association of progesterone receptor status with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer
BackgroundProgesterone receptor (PR)-negative tumors have been shown to have worse prognosis and were underrepresented in recent trials on patients...
-
Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer
PurposeRadiation therapy (RT) and hormone receptor (HR) inhibition are used for the treatment of HR-positive breast cancers; however, little is known...
-
Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancer
FOXM1 (Forkhead box M1) is an oncogenic transcription factor that is greatly upregulated in breast cancer and many other cancers where it promotes...
-
Insights adjusting for non-adherence in randomized clinical trials: a reanalysis of an adjuvant trial of tamoxifen duration in early breast cancer
BackgroundSeveral randomized clinical trials provide evidence of the survival benefit of extended adjuvant tamoxifen in women with estrogen receptor...
-
The phosphatidylinositol-transfer protein Nir3 promotes PI(4,5)P2 replenishment in response to TCR signaling during T cell development and survival
Hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP 2 ) by phospholipase C-γ (PLCγ1) represents a critical step in T cell antigen receptor (TCR)...
-
Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer
Both TP53 and ESR1 mutations occur frequently in estrogen receptor positive (ER+) metastatic breast cancers (MBC) and their distinct roles in breast...
-
The Ephrin tyrosine kinase a3 (EphA3) is a novel mediator of RAGE-prompted motility of breast cancer cells
BackgroundThe receptor for advanced glycation-end products (RAGE) and its ligands have been implicated in obesity and associated inflammatory...
-
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) have been approved in combination with endocrine therapy (ET) to treat estrogen...
-
The Impact of Anti-tumor Agents on ER-Positive MCF-7 and HER2-Positive SKBR-3 Breast Cancer Cells Biomechanics
Studying human cancer from a biomechanical perspective may contribute to pathogenesis understanding which leads to the malignancy. In this study,...
-
A prospective study of HER3 expression pre and post neoadjuvant therapy of different breast cancer subtypes: implications for HER3 imaging therapy guidance
PurposeHER3, a member of the EGFR receptor family, plays a central role in driving oncogenic cell proliferation in breast cancer. Novel HER3...
-
Racial disparity in tumor microenvironment and distant recurrence in residual breast cancer after neoadjuvant chemotherapy
Black, compared to white, women with residual estrogen receptor-positive (ER+) breast cancer after neoadjuvant chemotherapy (NAC) have worse distant...
-
Anticipating changes in the HER2 status of breast tumours with disease progression—towards better treatment decisions in the new era of HER2-low breast cancers
BackgroundHER2 expression is often negative or low in primary breast cancers (BCs) but its changes with disease progression remain poorly known. We...
-
Zinc Accumulation Aggravates Cerebral Ischemia/Reperfusion Injury Through Inducing Endoplasmic Reticulum Stress
Zinc is highly enriched in the central nervous system. Numerous evidences suggest that high concentration of zinc acts as a critical mediator of...
-
NNAT is a novel mediator of oxidative stress that suppresses ER + breast cancer
BackgroundNeuronatin (NNAT) was recently identified as a novel mediator of estrogen receptor-positive (ER+) breast cancer cell proliferation and...
-
Characterization of immune checkpoints expression and lymphocyte densities of iranian breast cancer patients; the co-expression status and clinicopathological associates
BackgroundBreast malignancies are now the most common and deadliest type of neoplasms among women worldwide. Novel therapeutic approaches are needed...
